MR Radiomic Features in Prostate Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04219059

Enrollment

200

Registered

2020-01-06

Start date

2019-09-03

Completion date

2021-03-30

Last updated

2023-01-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Keywords

cancer, prostate, radiomics, MRI, prognostic factors

Brief summary

A combination of correct interpretation of imaging and biopsy has given promising results in terms of detecting clinically significant cancer at radical prostatectomy.

Detailed description

Quantitative approaches to medical image analysis have been developed in recent years with the aim to overcome the limitation of qualitative image interpretation, and provide biomarkers for disease characterization. In particular, the new paradigm, radiomics, is emerging as the high-throughput extraction of quantitative features from imaging which can aid in characterizing phenotype as in vivo expression of tumoral genotype. The goal of radiomics is to extract accurate and reliable quantitative biomarkers which enhance diagnostic confidence in oncology. A combination of correct interpretation of imaging and biopsy has given promising results in terms of detecting clinically significant cancer at radical prostatectomy.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* \> 18 years of age * In house MRI with contrast medium * PCa (prostate cancer) biopsy proven diagnosis * In house radical prostatectomy

Exclusion criteria

* \< 18 years of age * MRI without contrast medium * Radical prostatectomy executed not in Institution

Design outcomes

Primary

Measure	Time frame	Description
Number of surrogate bioimaging markers of histological characteristics in MR images	0-2 years	Segment tumor volumes on the ADC map and extract different imaging features

Secondary

Measure	Time frame	Description
Radiomic features from MRI	0-2 years	Evaluate if radiomic features on primitive prostate lesions can describe lymph node involvement.
Extract radiomic features	0-2 years	Evaluate if radiomic features fro MRIon primitive prostate lesions can describe disease extension.

Countries

Italy

Outcome results